Article: article from journal or magazin.
Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study
Pathology, Research and Practice
Journal Article --- Old month value: Mar
With standard induction therapy between 50 to 85% of patients with Acute Myeloid Leukaemia (AML) achieve Complete Remission (CR). We investigated whether any morphological feature of bone marrow (BM) plastic embedded biopsies could predict failure of therapy. We reviewed BM plastic embedded biopsies from 54 adult patients presenting with untreated AML. The main histologic parameters analysed were cellularity, dysmegakaryopoiesis (DysM), percentage of marrow blasts and fibrosis. CR was obtained in 34 of 49 treated patients (69%). The rate of CR was significantly lower in the group of patients presenting with DysM: CR was achieved in 54% of the 28 treated patients with DysM and in 90% of the 21 treated patients without DysM (p less than 0.02). Patients with DysM had a significantly lower blood count and bone marrow blasts at presentation. Median age was not significantly different in the 2 groups. Cellularity and fibrosis were not predictive. DysM may be the hallmark of an AML subgroup with distinct clinical behaviour and lower rate of CR with conventional therapy. DysM should be carefully looked for on BM marrow biopsies and aspirate from AML patients at diagnosis.
Acute Disease Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Biopsy Blast Crisis/pathology Bone Marrow/pathology Female Humans Leukemia, Myeloid/drug therapy/*pathology Male Megakaryocytes/*pathology Middle Aged Prognosis Remission Induction/methods
Web of science
Last modification date